NOVO NORDISK A S
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Large accelerated filer
Business Address NOVO ALLE DK 2880, BAGSVAERD DENMARK, G7, 00000
Mailing Address NOVO ALLE DK 2880, BAGSVAERD DENMARK, G7, 00000
Phone 4544448888
Fiscal Year End 1231
EIN 000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | February 11, 2026 | View on SEC |
| 6-K Foreign company current report | February 10, 2026 | View on SEC |
| 6-K Foreign company current report | February 9, 2026 | View on SEC |
| 6-K Foreign company current report | February 5, 2026 | View on SEC |
| 6-K Foreign company current report | February 5, 2026 | View on SEC |
| 6-K Foreign company current report | February 5, 2026 | View on SEC |
| 6-K Foreign company current report | February 4, 2026 | View on SEC |
| 20-F Foreign company annual report | February 4, 2026 | View on SEC |
| 6-K Foreign company current report | February 3, 2026 | View on SEC |
| 6-K Foreign company current report | February 3, 2026 | View on SEC |
Annual Reports
20-F February 4, 2026
- Novo Nordisk delivered an exceptional year with robust growth, driven by innovative GLP-1 medicines like Ozempic, Rybelsus, and Wegovy.
- Net sales increased by 29% (CER) to DKK 232.3 billion, with operating profit up 37% (CER) and net profit soaring 51% year-over-year.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.